New induction therapies in renal transplantation;Nuevos tratamientos immunodepresores de inducció en le transplante renal

Medicina Clinica

Volumn 117, Issue 4, 2001, Pages 147-157

  Pascual, J ^a   Ortuno J ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Anti IL2r; Baxiliximab; Daclizumab; Induction therapy; Renal transplantation

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; INOLIMOMAB; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 2 RECEPTOR ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; ANTIBODY;

COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; REVIEW; ANIMAL; CLINICAL TRIAL; IMMUNOLOGY; METHODOLOGY; MOUSE;

ANIMALS; ANTIBODIES; CLINICAL TRIALS; HUMANS; IMMUNOSUPPRESSION; KIDNEY TRANSPLANTATION; MICE; RECEPTORS, INTERLEUKIN-2;

EID: 0035973067     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0025-7753(01)72044-1     Document Type: Review

References (94)

1. Immunosuppressive strategies in transplantation
2. Tratamiento inmunodepresor inicial en trasplante renal
3. A comparison of the effects of cyclosporine versus antilymphocyte globulin on delayed graft function in cadaver renal transplant recipients
4. A prospective randomized comparison of quadruple versus triple tharapy for first cadaver transplants with immediate function
5. Comparison of antilymphocyte globulin and continuous iv cyclosporin A as induction immunosuppression for cadaver kidney transplants: A prospective randomized study
6. Preliminary results of a prospective randomized clinical trial comparing cylosporine A to antithymocyte globulin immunosuppressive induction therapy in kidney transplantation
7. Advantage of antithymocyte globulin induction in sensitized kidney recipients: A randomized prospective study comparing induction with and without antithymocyte globulin
8. A randomized, double-blind comparison of thymoglobulin versus Atgam for induction immunosuppressive tharapy in adult renal transplant recipients
9. New usage paradigms in antibody therapy: Induction or true profilaxis?
10. Pharmacology of immunosuppressive medications used in renal diseases and transplantation
11. Release of tumor necrosis factor, interleukin-2 and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients
12. Cardiopulmonary effects of OKT3: Determinants of hypotension, pulmonary edema and cardiac dysfunction
13. OKT3-induced cytokine release: Attenuation by high-dose methylprednisolone
14. Acute clinical syndrome associated with OKT3 administration: Prevention by single injection of an anti-human TNF monoclonal antibody
15. Interleukin-10 inhibits OKT3-induced cytokine release: In vitro comparison with pentoxifylline
16. Use of indomethacin to minimize the adverse reactions associated with Orthoclone OKT3 treatment of kidney allograft rejection
17. Evidence that pentoxifylline reduces anti-CD3 monoclonal antibody-induced cytokine release syndrome
18. A prospective, double-blind randomized study of high versus lowdose OKT3 induction immunosuppression in cadaveric renal transplantation
19. Relevant targets for therapy with monoclonal antibodies in allograft tranplantation
20. Cytokine nephropathy during antilymphocyte therapy
21. Encephalopathy associated with OKT3 administration: Possible interaction with indomethacin
22. Complications and monitoring of OKT3 therapy
23. Increased infections associated with the use of OKT3 for treatment of steroid-resistant rejection in renal transplantation
24. Induction immunosuppression with antilymphocyte globulin or OKT3 in cadaver kidney transplantation
25. A comparison of rabbit antithymocyte serum and OKT3 as prophylaxis against renal allograft rejection
26. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients
27. Efficacy of rejection prophylaxis with OKT3 in renal transplantation
28. The effect of antilymphocyte induction therapy on renal allograft survival. A metaanalysis of individual patient data
29. Do prophylactic antilymphocyte globulins (ALG and OKT3) improve renal transplant survival in recipient and donor high-risk groups?
30. OKT3 prophylaxis in renal grafts with prolonged cold ischemia times: Association with improvement in long-term survival
31. Immunosuppressive therapy in high risk transplant patients: Dose-dependent efficacy of mycophenolate mofetil in African-American renal allograft patients
32. Could steroids be withdrawn in renal transplant patients sequentially treated with ATG, cyclosporine, and cellcept? One year results of a double blind, randomized, multicenter study comparing normal dose versus low dose and withdrawal of steroids
33. Cancer risk associated with ATG/OKT3 in renal transplantation
34. The interleukin-2 receptor
35. The structure, function and expression of interleukin-2 receptors on normal and malignant lymphocytes
36. A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells
37. A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. II. Expression of Tac antigen on activated cytotoxic killer T cells, suppressor cells, and on one of two types of helper T cells
38. Molecular cloning and expression of cDNAs for the human interleukin-2 receptor
39. Cloning, sequence and expression of human interleukin-2 receptor
40. Molecular cloning of cDNA encoding human interleukin-2 receptor
41. Cloning of the chain of the human IL-2 receptor
42. Prevention of rejection of kidney transplants by monoclonal antibody directed against interleukin-2 receptor
43. Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts
44. Prevention of acute rejection episodes with an anti-interleukin-2 receptor monoclonal antibody (II). Results after a second kidney transplantation
45. Prevention of acute rejection episodes with an anti-interleukin-2 receptor monoclonal antibody. I. Results after combined pancreas and kidney transplantation
46. A randomized prospective trial of anti. Tac monoclonal antibody in human renal transplantation
47. A double-blind, placebo-controlled study of monoclonal antiinterleukin-2 receptor antibody (BT563) administration to prevent acute rejection after kidney transplantation
48. Replacing the complementary-determining regions in a human antibody with those from a mouse
49. Anti-Tac-H, a humanized antibody to the interleukin-2 receptor with new features for immunotherapy in malignant and immune disorders
50. A humanized antibody that binds to the interleukin 2 receptor
51. Prolonged action of a chimeric interleukin-2 receptor (CD25) monoclonal antibody used in cadaveric renal transplantation
52. Pharmacokinetics and immunodynamics of himeric IL-2 receptor monoclonal antibody SDZ CHI 621 in renal allograft recipients
53. Disposition of basiliximab, an interleukin-2 receptor monoclonal antibody, in recipients of mismatched cadaver renal allografts
54. Disposition of basiliximab, a chimeric IL-2 receptor (CD25) monoclonal antibody, in pediatric renal transplant patients
55. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliimab, a chimeric antiinterleukin-2 receptor monoclonal antibody
56. Basiliximab (Simulect®) disminuye significativamente la incidencia de rechazo agudo en pacientes receptores de trasplante renal que reciben terapia triple con azatioprina
57. Basiliximab (Simulect®) es seguro y eftcaz en combinación con terapia triple de Sandimmun Neoral®, esteroides y Cellcept® en pacientes receptores de trasplante renal
58. The addition of basiliximab to cellcept, neoral and steroids resulted in a significant reduction in acute renal allograft rejection
59. Rapid steroid reduction in kidney transplant recipients with Simulect, neoral and cellcept
60. Retirada rápida de esteroides versus una pauta de esteroides estándar en pacientes tratados con Simulect®, Sandimmun Neoral® y micofenolato mofetil para la prevención del rechazo agudo en trasplante renal
61. Controlled trial of IL-2R antibody basiliximab (Simulect) versus low dose OKT3 in cadaver kidney transplant recipients
62. A randomized prospective trial of OKT3 vs basiliximab for induction therapy in renal transplantation
63. Improved outcome in renal transplant recipients treated with Simulect versus OKT3 induction
64. Simulect induction is safer and more effective than OKT3 in kidney recipients older than 60 years
65. Induction strategy using basiliximab combined with mycophenolate and immediate low dose cyclosporin is steroid sparing and more effective than OKT3
66. Comparison of basiliimab to rabbit anti-thymogyte globulin induction in kidney transplant recipients
67. A multicenter, randomized trial of Simulect® versus Thymoglobuline® in renal transplantation
68. Multicenter study of the safety and tolerability of basiliximab (Simulect®) in de novo pediatric renal transplantation
69. Basiliximab (Simulect®) dramatically reduces acute rejection after pediatric kidney transplantation
70. Interleukin-2 receptor antibody-induced alterations of ciclosporin dose requirements in paediatric transplant recipients
71. Low kidney rejection rates with basiliximab induction and delayed introduction of tacrolimus for patients with delayed graft function
72. A calcimeurin-free strategy for induction immune suppression for delayed graft function in cadaveric kidney transplantation
73. Reduced acute rejection and superior 1-year renal allograft survival with basiliximab in patients with diabetes mellitus
74. Basiliximab vs OKT3 in primary simultaneous pancreas-kidney transplant recipients
75. A multicenter trial of Simulect® in combination with Neoral®, Cellcept® and steroids for the prevention of acute rejection in kidney-pancreas transplantation: A low rate of rejection without recurrent diabetes mellitus
76. Basiliximab induction versus no induction in simultaneous kidney pancreas transplantation using mycophenolate/tacrolimus/prednisone maintenance immunosuppression
77. Reduced immunogenicity and improved pharmacokinetics of humanized anti-Tac in cynomolgus monkeys
78. Anti-Tac-H, a humanized antibody to the interleukin-2 receptor, prolongs primate cardiac allograft survival
79. A phase I trial of humanized anti-interleukin-2 receptor antibody in renal transplantation
80. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation
81. Reduction of acute renal allograft rejection by daclizumab
82. Cytomegalovirus infections after treatment with daclizumab, an anti-IL-2 receptor antibody, for prevention of renal allograft rejection
83. Three year outcome of the phase III clinical trials with daclizumab
84. Can antibody prophylaxis allow sparing of other immunosuppressives
85. Zenapax versus OKT3 prophylaxis in immunologically high risk kidney transplant recipients
86. Clinical experience with a two dose regimen of daclizumab in cadaveric renal transplantation
87. One or two doses of daclizumab provide effective immunosuppression for renal transplant patients with high immunologic risk or with delayed graft function
88. A two dose regimen of daclizumab (Zenapax) in high-risk renal transplant recipients
89. Daclizumab decreases acute rejection in african american and hispanic renal transplant recipients
90. Daclizumab permits delayed introduction of calcineurin inhibitors in renal transplant recipients at risk for delayed graft funtion
91. Comparison of daclizumab vs ATGAM induction in kidney pancreas transplantation
92. An open-label comparative trial of two daclizumab dosing strategies versus no antibody induction combined with tacrolimus, mycophenolate mofetil, and steroids for the prevention of acute rejection in simultaneous kidney/pancreas recipients: Interim analysis